Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs

American Journal of Gastroenterology

Volumn 97, Issue 12, 2002, Pages 2950-2961

  Quan, Carolyn ^a   Talley, Nicholas J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIULCER AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; FLOXURIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; LANSOPRAZOLE; MISOPROSTOL; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PENTAGASTRIN; POTASSIUM CHLORIDE; RANITIDINE; SALICYLIC ACID; STOMACH SECRETION INHIBITOR;

CLINICAL TRIAL; DEATH; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DUODENUM ULCER; ERADICATION THERAPY; GASTROINTESTINAL HEMORRHAGE; GENETIC PREDISPOSITION; GEOGRAPHIC DISTRIBUTION; HELICOBACTER HEILMANNII; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; MAINTENANCE THERAPY; MENTAL STRESS; META ANALYSIS; MUCOSAL IMMUNITY; PATHOGENESIS; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; RELAPSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SMOKING; STOMACH BIOPSY; STOMACH EMPTYING; STOMACH PERFORATION; STOMACH PH; STOMACH ULCER; TREATMENT OUTCOME; ULCEROGENESIS; ZOLLINGER ELLISON SYNDROME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER;

EID: 0036896179     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)05485-0     Document Type: Review

References (121)

1. Marshall BJ, McGechie DB, Rogers PA, et al. Pyloric campylobacter infection and gastroduodenal disease. Med J Aust 1985;142:439-44.
2. Xia HH-X, Phung N, Kalantar J, et al. Demographic and endoscopic characteristics of patients with Helicobacter pylori positive and negative peptic ulcer disease. Med J Aust 2000;173:515-9.
3. Meucci G, Di Battista R, Abbiati C, et al. Prevalence and risk factors of Helicobacter pylori-negative peptic ulcer. J Clin Gastroenterol 2000;31:42-7.
4. Ciociola AA, McSorley DJ, Turner K, et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999;94:1834-40.
5. Bytzer PB, Teglbjaerg PS, and the Danish Ulcer Study Group. Helicobacter pylori-negative duodenal ulcers: Prevalence, clinical characteristics, and prognosis - Results from a randomized trial with 2-year follow-up. Am J Gastroenterol 2001;96:1409-16.
6. Arakawa T, Higuchi K, Fujiwara Y, et al. Helicobacter pylori: Criminal or innocent bystander? J Gastroenterol 2000; 35(suppl XII):42-6.
7. Gisbert JP, Blanco M, Mateos JM, et al. H. pylori-negative duodenal ulcer: Prevalence and causes in 774 patients. Dig Dis Sci 1999;44:2295-302.
8. Schubert M, Richmond VA, DeWitt JM, et al. Prospective evaluation of the prevalence of H. pylori in duodenal and gastric ulcer: Is its role overstated? Gastroenterology 1999; 116:A305 (abstract).
9. Ng EKW, Chung SCS, Sung JJY, et al. High prevalence of Helicobacter pylori infection in duodenal ulcer perforations not caused by non-steroidal anti-inflammatory drugs. BMJ 1996;83:1779-81.
10. Sprung DJ, Apter MN. What is the role of Helicobacter pylori in peptic ulcer and gastric cancer outside the big cities? J Clin Gastroenterol 1998;26:60-3.
11. Aoyama N, Shinoda Y, Matsushima Y, et al. Helicobacter pylori-negative peptic ulcer in Japan: Which contributes most to peptic ulcer development, Helicobacter pylori, NSAIDs or stress? J Gastroenterol 2000;35(suppl XII):33-7.
12. Nishikawa K, Sugiyama T, Kato M, et al. Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol 2000;12:635-40.
13. Higuchi K, Arakawa T, Fujiwara Y, et al. Is Helicobacter pylori-negative duodenal ulcer masked by the high prevalence of H. pylori infection in the general population? Am J Gastroenterol 1999;94:3083-4.
14. Tsuji H, Kohli Y, Fukumitsu S, et al. Helicobacter pylorinegative gastric and duodenal ulcers. J Gastroenterol 1999; 34:455-60.
15. Henriksson AE, Edman AC, Nilson I, et al. Helicobacter pylori and the relation to other risk factors in patients with acute bleeding peptic ulcer. Scand J Gastroenterol 1998;33: 1030-3.
16. Uyub AM, Raj SM, Visvanathan R, et al. Helicobacter pylori infection in north-eastern peninsular Malaysia. Scand J Gastroenterol 1994;29:209-13.
17. Borody T, Brandl S, Andrews P, et al. Helicobacter pylorinegative gastric ulcer. Am J Gastroenterol 1992;87:1403-6.
18. Borody TJ, George LL, Brandl S, et al. Helicobacter pylorinegative duodenal ulcer. Am J Gastroenterol 1991;86: 1154-7.
19. Nensey YW, Schubert TT, Bologna SD, et al. Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol 1991;91: 15-8.
20. Vu C, Ng YY. Prevalence of Helicobacter pylori in peptic ulcer disease in a Singapore Hospital. Singapore Med J 2000;41:478-81.
21. Henry A, Batey RG. Low prevalence of Helicobacter pylori in an Australian duodenal ulcer population: NSAIDitis or the effect of ten years of H. pylori treatment? Aust N Z J Med 1998;28:345.
22. Jyotheeswaran S, Shah AN, Jin HO, et al. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: Is empirical triple therapy justified? Am J Gastroenterol 1998;93:574-8.
23. Gislason GT, Emu B, Okolo P III, et al. Where have all the Helicobacter pylori gone? Etiologic factors in patients with duodenal ulcers presenting to a university hospital. Gastrointest Endosc 1997;45:263 (abstract).
24. Hyvarinen H, Salmenkyla S, Sipponen P. Helicobacter pylori-negative duodenal and pyloric ulcer: Role of NSAIDs. Digestion 1996;57:305-9.
25. McColl KEL, El-Nujumi AM, Chittajallu RS, et al. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut 1993;34:762-8.
26. Fujisawa T, Kumagai T, Akamatsu T, et al. Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Am J Gastroenterol 1999;94:2094-9.
27. Sugiyama T, Nishikawa K, Komatsu Y, et al. Attributable risk of H. pylori in peptic ulcer disease: Does declining prevalence of infection in general population explain increasing frequency of non-H. pylori ulcers? Dig Dis Sci 2001;46: 307-10.
28. Goh KL. Prevalence of and risk factors for Helicobacter pylori infection in a multi-racial dyspepsia Malaysian population undergoing endoscopy. J Gastroenterol Hepatol 1997; 12(suppl):S29-S35.
29. Hu PJ, Zhou MH, Chen MH, et al. Helicobacter pylori associated with a high prevalence of duodenal ulcer disease and a low prevalence of gastric cancer in a developing nation. Gut 1995;36:198-202.
30. Wang JY, Liu SB, Chen SY, et al. Risk factors for peptic ulcer in Shanghai. Int J Epidemiol 1996;25:638-43.
31. Yee YK, Chang KK, Li KF, et al. Decreasing prevalence of H. pylori infection in patients with peptic ulcer diseases. Gastroenterology 2000;118:A728 (abstract).
32. Kemppainen H, Raiha I, Sourander L. Clinical presentation of peptic ulcer in the elderly. Gerontology 1997;43:283-8.
33. Hirschowitz BI, Mohnen J, Shaw S. High recurrence rate of duodenal ulcer despite H. pylori eradication in a clinical subset-rapidly recurring peptic ulcer. Gastroenterology 1994; 106:A94 (abstract).
34. Peterson WL, Ciociola AA, Sykes DL, et al. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. Aliment Pharmacol Ther 1996;10:251-61.
35. Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? Am J Gastroenterol 1998;93:1409-15.
36. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2:1437-42.
37. Reinbach DH, Cruishank G, McColl KEL. Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection. Gut 1993;34:1344-7.
38. Ng EKW, Chung SCS, Sung JJY, et al. High prevalence of Helicobacter pylori infection in duodenal ulcer perforations not caused by non-steroidal anti-inflammatory drugs. BMJ 1996;83:1779-81.
39. Hosking SW, Yung MY, Chung SC, et al. Differing prevalence of Helicobacter in bleeding and nonbleeding ulcers. Gastroenterology 1992;102:A85 (abstract).
40. Lee JM, Breslin NP, Fallon C, et al. Rapid urease tests lack sensitivity in Helicobacter pylori diagnosis when peptic ulcer disease presents with bleeding. Am J Gastroenterol 2000;95: 1166-70.
41. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid Suppression Trial: Ranitidine Versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998;338:719-26.
42. Gisbert JP, Blanco M, Mateos JM, et al. H. pylori-negative duodenal ulcer: Prevalence and causes in 774 patients. Dig Dis Sci 1999;44:2295-302.
43. Laine L, Estrada R, Trujillo M, et al. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998;129:547-50.
44. 14C-urea breath test by a pH-dependent mechanism. Am J Gastroenterol 1997;92: 446-50.
45. Hazel SL, Henessey WB, Borody TJ, et al. Campylobacter pyloridis gastritis II: Distribution of bacteria and associated inflammation in the gastroduodenal environment. Am J Gastroenterol 1987;82:297-301.
46. Goodwin CS, Blincow ED, Warren JR, et al. Evaluation of cultural techniques for isolating Campylobacter pyloridis from endoscopic biopsies of gastric mucosa. J Clin Pathol 1985;38:1127-31.
47. Morris A, Ali MR, Brown P, et al. Campylobacter pylori infection in biopsy specimens of gastric antrum: Laboratory diagnosis and estimation of sampling error. J Clin Pathol 1989;42:727-32.
48. Bayerdorffer E, Oertel H, Lehn N, et al. Topographic association between active gastritis and Campylobacter pylori colonisation. J Clin Pathol 1989;42:834-9.
49. Logan RPH, Walker MM, Misiewicz WJJ, et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995;36:12-6.
50. Dickey W, Kenny BD, McConnell JB. Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies. Aliment Pharmacol Ther 1996;10:289-93.
51. Graham DY, Genta R, Evans DG, et al. Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole. Am J Gastroenterol 1996;91:2120-4.
52. Farinati F, Valiante F, Germana B, et al. Prevalence of Helicobacter pylori infection in patients with precancerous changes and gastric cancer. Eur J Cancer Prev 1993;2:321-6.
53. Annibale B, Marignani M, Azzoni C, et al. Atrophic body gastritis: Distinct features associated with Helicobacter pylori infection. Helicobacter 1997;2:57-64.
54. Johnston BJ, Reed PI, Ali MH. Prevalence of Campylobacter pylori in duodenal and gastric mucosa - Relationship to inflammation. Scand J Gastroenterol 1988;23:69-75.
55. Leung WK, Sung JJY, Siu KLK, et al. False-negative biopsy urease test in bleeding ulcers caused by the buffering effects of blood. Am J Gastroenterol 1998;93:1914-8.
56. Tu TC, Lee CL, Wu CH, et al. Comparison of invasive and noninvasive tests for detecting Helicobacter pylori infection in bleeding peptic ulcers. Gastrointest Endosc 1999;49: 302-6.
57. Fletcher RH, Fletcher SW, Wagner EH. Clinical Epidemiology: The Essentials, 3rd Ed. Baltimore, MD: Williams & Wilkins, 1996;43-74.
58. Laine L, Estrada R, Trujillo M, et al. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998;129:547-50.
59. Laine L, Cohen H. Helicobacter pylori: Drowning in a pool of blood? Gastrointest Endosc 1999;49:398-402.
60. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000;119:521-35.
61. Piper DW, McIntosh JH, Ariotti DE, et al. Analgesic ingestion and chronic peptic ulcer. Gastroenterology 1981;80: 427-32.
62. Piper DW, Nasiry R, McIntosh J, et al. Smoking, alcohol, analgesics, and chronic duodenal ulcer. Scand J Gastroenterol 1984;19:1015-21.
63. Lanas A, Serrano P, Bajador E, et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997;112:683-9.
64. Lanas AI, Remacha B, Esteva F, et al. Risk factors associated with refractory peptic ulcers. Gastroenterology 1995;109: 1124-33.
65. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): A review. Alternative Med 2000;5:334-46.
66. Graf J, Herbal anti-inflammatory agents for skin disease. Skin Ther Letter 2000;5:3-5.
67. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole Versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727-34.
68. Graham DY, Malaty HM. Alendronate gastric ulcers. Aliment Pharmacol Ther 1999;13:515-9.
69. Blank MA, Gibson GW, Myers WR, et al. Nonclinical model for assessing gastric effects of bisphosphonates. Dig Dis Sci 1997;42:281-8.
70. Geddes AD, D'Souza SM, Ebetino FH, et al. Bisphosphonates: Structure-activity relationships and therapeutic implications. In: Heersche JNM, Kanis JA, eds. Bone and Mineral Research, vol. 8. Amsterdam: Elsevier Science, 1994:265-306.
71. Sinar DR, Bozymski EM, Blackshear JL. Effects of oral potassium supplements on upper gastrointestinal mucosa: Multicenter clinical comparison of three formulations and placebo. Clin Ther 1986;8:157-63.
72. Sharma R, Organ CH Jr, Hirvela ER, et al. Clinical observation of the temporal association between crack cocaine and duodenal ulcer perforation. Am J Surg 1997;174:629-32.
73. Arrillaga A, Sosa JL, Najjar R. Laparoscopic patching of crack cocaine-induced perforated ulcers. Am Surg 1996;62: 1007-9.
74. Doria MI Jr, Doria LK, Faintuch J, et al. Gastric mucosal injury after hepatic arterial infusion chemotherapy with floxuridine: A clinical and pathological study. Cancer 1994; 73:2042-7.
75. Deveney CW, Deveney KE. Zollinger-Ellison syndrome (gastrinoma): Current diagnosis and treatment. Surg Clin North Am 1987;67:411-22.
76. Fich A, Talley NJ, Shorter RG, et al. Zollinger-Ellison syndrome: Relation to Helicobacter pylori-associated chronic gastritis and gastric acid secretion. Dig Dis Sci 1991; 36:10-4.
77. Koop H, Stumpf M, Eissele R, et al. Antral Helicobacter pylori-like organisms in different states of gastric acid secretion. Digestion 1991;48:230-6.
78. Saeed ZA, Evans DJ Jr, Evans DG, et al. Helicobacter pylori and Zollinger-Ellison syndrome. Dig Dis Sci 1991;36:15-8.
79. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome: Clinical presentation in 261 patients. Medicine 2000;79:379-411.
80. Prinz RA. Localization of gastrinomas. Int J Pancreatol 1996; 19:79-91.
81. Thom AK, Norton JA, Doppman JL. Prospective study of the use of intraarterial secretin injection and portal venous sampling to localise duodenal gastrinomas. Surgery 1992;112: 1002-8.
82. Goddard AF, Logan RPH, Atherton JC, et al. Healing of duodenal ulcer after eradication of Helicobacter heilmannii. Lancet 1997;349:1815-6.
83. Debongnie JC, Donnay M, Mairesse J, et al. Gastric ulcers and Helicobacter heilmannii. Eur J Gastroenterol Hepatol 1998;10:251-4.
84. Stolte M, Kroher G, Meining A, et al. A comparison of Helicobacter pylori and H. heilmannii gastritis. Scand J Gastroenterol 1997;32:28-33.
85. Stolte M, Wellens E, Bethke B, et al. Helicobacter heilmannii (formerly Gastrospirillum hominis) gastritis: An infection transmitted by animals? Scand J Gastroenterol 1994;29: 1061-4.
86. Yang H, Goliger J, Song M, et al. High prevalence of Helicobacter heilmannii infection in China. Dig Dis Sci 1998; 43:1493-4.
87. Heilmann KL, Borchard F. Gastritis due to spiral shaped bacteria other than Helicobacterpylori: Clinical, histological, and ultrastructural findings. Gut 1991;32:137-40.
88. Queiroz DM, Rocha GA, Mendes EN, et al. Association between Helicobacter and gastric ulcer disease of the pars esophagea in swine. Gastroenterology 1996;111:19-27.
89. Yamamoto T, Matsumoto J, Shiota K, et al. Helicobacter heilmannii associated erosive gastritis. Int Med 1999;38: 240-3.
90. Varsky CG, Correa MC, Sarmiento N, et al. Prevalence and etiology of gastroduodenal ulcer in HIV-positive patients: A comparative study of 497 symptomatic subjects evaluated by endoscopy. Am J Gastroenterol 1998;93:935-40.
91. Arnar DO, Gudmundsson G, Theodors A, et al. Primary cytomegalovirus infection and gastric ulcers in normal host. Dig Dis Sci 1991;36:108-11.
92. Lohr JM, Nelson JA, Oldstone MBA. Is herpes simplex virus associated with peptic ulcer disease? J Virol 1990;64:2168-74.
93. Cherner JA, Jensen RT, Dubois A, et al. Gastrointestinal dysfunction in systemic mastocytosis: A prospective study. Gastroenterology 1988;95:657-67.
94. Koop H, Koop I, Klein M, et al. Irradiation-induced duodenal ulcer refractory to ranitidine: Healing by omeprazole. J Clin Gastroenterol 1989;11:631-4.
95. Urayama S, Kozarek R, Ball T, et al. Presentation and treatment of annular pancreas in an adult population. Am J Gastroenterol 1995;90:995-9.
96. Harris AW, Gummett PA, Phull PS, et al. Recurrence of duodenal ulcer after Helicobacter pylori eradication is related to high acid output. Aliment Pharmacol Ther 1997;11:331-4.
97. Rotter JI. Peptic ulcer. In: Emery AEH, Rimoin DL, eds. The Principles and Practice of Medical Genetics. New York: Churchill Livingstone, 1983:863-78.
98. Malaty H, Graham DY, Isaksson I, et al. Are genetic influences on peptic ulcer dependent or independent of genetic influences for Helicobacter pylori infection? Arch Intern Med 2000;160:105-9.
99. Raiha I, Kemppainen H, Kaprio J, et al. Lifestyle, stress, and genes in peptic ulcer disease: A nationwide twin cohort study. Arch Intern Med 1998;158:698-704.
100. Friedman GD, Siegelaub AB, Seltzer CC. Cigarettes, alcohol, coffee and peptic ulcer. N Engl J Med 1974;290:469-73.
101. Korman MG, Hansky J, Eaves R, et al. Influence of cigarette smoking on healing and relapse in duodenal ulcer disease. Gastroenterology 1983;85:871-4.
102. Piper DW, McIntosh JH, Hudson HM. Factors relevant to the prognosis of chronic duodenal ulcer. Digestion 1985;31:9-16.
103. Armstrong D, Arnold R, Classen M, et al. RUDER - A prospective, two year, multicenter study of risk factors for duodenal ulcer relapse during maintenance therapy with ranitidine. RUDER Study Group. Dig Dis Sci 1994;39:1425-33.
104. Sonnenberg A, Muller-Lissner SA, Vogel E, et al. Predictors of duodenal ulcer healing and relapse. Gastroenterology 1981;81:1061-7.
105. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer: Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997;24:2-17.
106. Borody TJ, George LL, Brandl S, et al. Smoking does not contribute to duodenal ulcer relapse after Helicobacter pylori eradication. Am J Gastroenterol 1992;87:1390-3.
107. Ehdoh K, Leung FW. Effects of smoking and nicotine on the gastric mucosa: A review of clinical and experimental evidence. Gastroenterology 1994;107:864-78.
108. Shay H. Etiology of peptic ulcer. Am J Dig Dis 1961;6:29- 49.
109. Eastwood GL. Is smoking still important in the pathogenesis of peptic ulcer disease? J Clin Gastroenterol 1997;25(suppl 1):S1-S7.
110. Levenstein S. The very model of a modern etiology: A biopsychosocial view of peptic ulcer. Psychosom Med 2000; 62:176-85.
111. Feldman M, Walker P, Green JL, et al, Life events stress and psychosocial factors in men with peptic ulcer disease. Gastroenterology 1986;91:1370-9.
112. Weisman AD. A study of psychodynamics of duodenal ulcer exacerbations: With special reference to treatment and the problem of "specificity." Psychosom Med 1956;18:2-42.
113. Levenstein S, Ackerman S, Kiecolt-Glaser JK, et al. Stress and peptic ulcer disease. JAMA 1999;281:10-11.
114. Peters MN, Richardson CT. Stressful life events, acid hypersecretion, and ulcer disease. Gastroenterology 1983;84: 114-9.
115. Piper DW, Greig M, Shinners J, et al. Chronic gastric ulcer and life events. Gastroenterology 1980;78:905-11.
116. Thomas J, Greig M, Piper DW. Chronic gastric ulcer and life events. Gastroenterology 1980;78:905-11.
117. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Helicobacter pylori eradication in patients taking non-steroidal anti-inflammatory drugs. The HELP NSAIDs Study. Lancet 1998; 352:1016-21.
118. Chan FKL, Chung S, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73.
119. Keppainen H, Raiha I, Sourander L. Clinical presentation of peptic ulcer in the elderly. Gerontology 1997;43:283-8.
120. Cryer B, Redfern JS, Goldschmiedt M, et al. Effect of aging on gastric and duodenal mucosal prostaglandin concentrations in humans. Gastroenterology 1992;102:1118-23.
121. Gillen D, Wirz AA, Neithercut WD, et al. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 1999;44:468-75.